Warrants for 1.5 Million Ordinary Shares in the Form of American Depository Shares Expired on November 29, 2018
Capital Structure Now Comprised Exclusively of Common Stock
LYON, France, November 29, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that warrants for 1.5 million ordinary shares in the form of American Depository Shares (ADSs) expired on November 29, 2018. This expiration follows the earlier expiration of warrants for approximately 3.3 million ordinary shares in the form of American Depository Shares (ADSs) on October 14, 2018.
"The expiration of this second tranche of warrants, together with the earlier expiration that we announced on October 14, provide us with a greatly simplified capital structure that is now comprised exclusively of common shares," said Marc Oczachowski, Chief Executive Officer of EDAP. "As we work to expand the commercial footprint for our novel Focal One HIFU device into new commercial territories, including the U.S., potential investors can focus on the strengthening fundamentals of our business without the overhang that these warrants represented."
On May 28, 2013, pursuant to a securities purchase agreement dated May 20, 2013, the Company issued 3,000,000 ordinary shares in the form of ADSs to certain institutional investors in a registered direct placement, at a price of $4.00 per share, with warrants attached that allow investors to purchase up to 1,500,000 new shares in the form of ADSs, at an exercise price of $4.25 per share.
On April 14, 2016, pursuant to a securities purchase agreement dated April 7, 2016, the Company issued 3,283,284 ordinary shares in the form of ADSs to certain institutional investors in a registered direct placement, at a price of $3.50 per share, with warrants attached that allow investors to purchase up to 3,283,284 new shares in the form of ADSs, at an exercise price of $4.50 per share.
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
LifeSci Advisors, LLC
Source: EDAP TMS S.A.